Table 2 Clinical and demographic factors associated with chemotherapy receipt in BRCA1/2 and PALB2 carriers with operable breast cancer (n = 309)
Characteristic | Cohort | Proportion receiving chemotherapy | |
|---|---|---|---|
No. (%) | % | p-value | |
Germline Pathogenic Variant (GPV) – n, (%) |  |  | < 0.001 |
 BRCA1 | 160 (51.8) | 80.6 |  |
 BRCA2 | 130 (42.1) | 56.9 |  |
 PALB2 | 19 (6.2) | 84.2 |  |
Age at Index Breast Cancer Diagnosis – n, (%) |  |  | 0.040 |
 <30 years | 29 (9.4) | 84.6 |  |
 30–40 years | 91 (29.5) | 72.4 |  |
 40–50 years | 91 (29.5) | 74.4 |  |
 50–60 years | 63 (20.4) | 54.7 |  |
 60 + years | 35 (9.5) | 11.3 |  |
Biopsy Histology – n, (%) |  |  | < 0.001 |
 Ductal carcinoma in situ (DCIS) | 31 (10.3) | 0.0 |  |
 Invasive ductal carcinoma | 228 (73.8) | 84.2 |  |
 Invasive lobular carcinoma | 12 (3.9) | 66.7 |  |
 Other/unknown | 38 (12.3) | 50.0 |  |
Histologic Grade* |  |  | < 0.001 |
 Grade I | 7 (2.5) | 14.3 |  |
 Grade II | 73 (26.3) | 69.9 |  |
 Grade III | 198 (71.2) | 84.3 |  |
Biologic Subtype* – n, (%) |  |  | 0.006 |
 HR + HER2- | 92 (43.6) | 73.9 |  |
 HER2+ | 12 (5.7) | 91.7 |  |
 TNBC | 108 (50.9) | 90.0 |  |
Tumour Size* – n, (%) |  |  | < 0.001 |
 cT1a-b | 36 (13.0) | 50.0 |  |
 cT1c | 66 (23.7) | 87.9 |  |
 cT2 | 104 (37.4) | 96.2 |  |
 cT3-T4 | 23 (8.3) | 95.7 |  |
 Unknown | 49 (17.6) | 42.9 |  |
Nodal Status* – n, (%) |  |  | < 0.001 |
 cN0 | 210 (75.5) | 72.3 |  |
 cN1-N2 | 68 (24.5) | 98.5 |  |